Neuroscience & Stroke Education Series: Update on the Treatment of Alzheimer's Disease: Aducanumab Recorded Session

This session is part of the Neuroscience & Stroke Education Series. 

In this session, you will gain an understanding of Alzheimer’s Disease and current treatments. Clinical trials and studies will be discussed to gain knowledge on the successes/fails of different treatment options.

If you attended Update on the Treatment of Alzheimer's Disease: Aducanumab on February 24, 2022, you will not be able to claim credit again for this course. However, you are welcome to still watch the content.

Target Audience

This course is intended for all physicians including generalists, neurologists, intensivists, radiologists, and pathologists, RN's, PA's, NP's, RTT's, and various other members of the health care team

Learning Objectives

At the end of this session, learners should be able to:

  1. Identify current treatments for patients with Alzheimer’s Disease
  2. Apply knowledge from clinical trials and studies into practice
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
    Attendance Credit
    • 1.00 Approved AMA PRA Category 1 Credit™
Course opens: 
02/24/2022
Course expires: 
02/24/2025
Cost:
$0.00
Part of: 
Neuroscience & Stroke Education Series Recorded Sessions
Rating: 
0

Faculty

Darren Gitelman, MD; Advocate Aurora Health
Eric Maas, MD; Advocate Aurora Health
Paul Vilar, MSN, RN, SCRN; Advocate Aurora Health
Rachael Wade, MHA; Advocate Aurora Health
Amy Campbell, Executive Assistant; Advocate Aurora Health

 

Disclosure

The following faculty speakers and/or planning committee members have disclosed the following:

Faculty Name

Name of Ineligible Companies

Nature of Relationship

Darren Gitelman, MD

-Biogen
-Eisai; Lilly; Abbvie
-Novartis

-Research Funding, Speaking fees
-Research Funding
-Consultant

The other planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated.

Accreditation Statement
In support of improving patient care, Advocate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Statement(s)

American Medical Association (AMA) 
Advocate Health designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
    Attendance Credit
    • 1.00 Approved AMA PRA Category 1 Credit™

Price

Cost:
$0.00
Please login or register to take this course.

 

If you attended Update on the Treatment of Alzheimer's Disease: Aducanumab on February 24, 2022, you will not be able to claim credit again for this course. However, you are welcome to still watch the content.

Click “Take Course” to register for this program.  

If you have any questions, please contact the IPCE Office at cme@aah.org